OECD Home › Directorate for Science, Technology and Industry › Science and technology policy › Latest Documents
The aim of the OECD Global Forum on the Knowledge Economy (GFKE) is to strengthen the OECD’s Global Relations in the areas of work covered by four DSTI Committees.
Patent indicators are used to map aspects of the innovative performance and technological progress of countries, regions or certain specific domains and technology fields.
The aim of this consultation, held on 20-21 June 2013 in Oxford (UK), was to stimulate discussion at the highest possible level of expert engagement in setting out an agenda for OECD action to accelerate innovation for Alzheimer’s disease and dementia.
The economic and social impact of chronic brain disorders such as Alzheimer’s and other neurodegenerative diseases will become the #1 public health problem worldwide by 2050, directly affecting 100 million people. Ongoing demographic trends, namely ageing populations, are leading to the unprecedented expansion of consumer demand for healthcare services, which will confront a serious crisis in a climate of shrinking resources.
Countries/regions have begun to develop and refine regulatory approaches for foods and medical products and invest in regulatory science and other research efforts to support the responsible development of nanotechnology in these areas. This paper inventories and analyses regulatory approaches, legislative regimes and government-sponsored research programmes and infrastructure in foods and medical products that involve nanotechnology.
The April 2013 meeting of the OECD Global Forum saw the official launch of Scientific Collections International (SciColl), a new international network devoted to promoting interdisciplinary research that relies on scientific collections.
OECD Global Science Forum report on data and research infrastructure for the social sciences.
This framework introduces a risk-based oversight and management methodology for clinical trials. It combines a stratified approach that is based on the marketing authorisation status of the medical product and can be applied in a common manner across countries’ regulatory frameworks, with a trial-specific approach that considers other issues such as the type of populations concerned by the trial, or the informed consent of the patients.
Data set on R&D expenditure by industry which addresses the problems of international comparability and breaks in the time series of the official business enterprise R&D data.
This paper presents a new edition of the project's technical guidelines including methodological guidelines, a core model questionnaire and instruction manual, and the output tables used for reporting data at the international level and related definitions.